Stockreport

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF - Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl -- Strong cash position of [Read more]